PLX · Protalix BioTherapeutics, Inc.
$2.30
+0.08 (+3.60%)
At close · Aug 17
Market Cap
$178.87M
Shares
80.57M
Protalix BioTherapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Protalix BioTherapeutics, Inc. (PLX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲17.7%
$14.18M
−$3.57M
'22 Q3
22-11-14
▲0.8%
$8.62M
−$3.74M
'22 Q4
23-02-27
▼40.4%
$9.59M
−$3.13M
'23 Q1
23-05-04
▲300.7%
$35.08M
$19.34M
'23 Q2
23-08-07
▼27.1%
$10.35M
−$1.85M
'23 Q3
23-11-06
▲21.7%
$10.49M
−$6.04M
'23 Q4
24-03-14
▼60.9%
$3.75M
−$4.59M
'24 Q1
24-05-10
▼61.6%
$13.47M
−$2.20M
'24 Q2
24-08-14
▲73.6%
$17.96M
$3.24M
'24 Q3
24-11-14
▲73.7%
$18.22M
$6.49M
'24 Q4
25-03-17
▲169.8%
$10.11M
−$3.62M
'25 Q1
25-05-09
▲16.2%
$15.66M
$164,000
'25 Q2
25-08-14
▼0.6%
$17.85M
$2.35M
'25 Q3
25-11-13
▼49.9%
$9.12M
−$5.50M
'25 Q4
26-03-18
▲233.7%
$33.75M
$18.32M
'26 Q1
26-05-13
LATEST
▲27.1%
$19.90M
$3.78M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Protalix Biotherapeutics Second Quarter 2026 Financial and Business Results Conference Call
Positive tone
Phase 2 study regimens (E4W/E8W with/without methotrexate)
Phase 3 dose selection and ADA/PK/PD considerations
Elfabrio (commercial product) performance and lumpy orders
Revenue
$19.90M
▲ 27.1% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Protalix BioTherapeutics, Inc. Q1 FY2026 Earnings Call
Positive tone
Elfabrio every 4-week approval and commercial uptake
PRX-115 Phase II RELEASE study in uncontrolled gout
Balance sheet and financial flexibility
Revenue
$33.75M
▲ 233.7% YoY Diluted EPS
$0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-18
Protalix BioTherapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
Elfabrio EU Every-4-Weeks Approval
Chiesi Partnership and Revenue Growth
2026 Revenue Guidance
Revenue
$9.12M*
▼ 49.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Protalix BioTherapeutics, Inc. Q3 FY2025 Earnings Call
Positive tone
Quarterly and Year-to-Date Revenue Performance
Elfabrio CHMP Reexamination (Q4W Dosing)
PRX-115 Phase 2 Trial in Uncontrolled Gout
Revenue
$17.85M
▼ 0.6% YoY Diluted EPS
$0.03
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Protalix BioTherapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone
Elfabrio Commercialization with Chiesi
CFO Transition
EMA Once-Every-4-Weeks Dosing Variation
Revenue
$15.66M
▲ 16.2% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Protalix BioTherapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone
Tariffs and international tax exposure
PRX-115 clinical development in gout
Operating costs and R&D spend
Revenue
$10.11M
▲ 169.8% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
Protalix BioTherapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$18.22M*
▲ 73.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Protalix BioTherapeutics, Inc. Q3 FY2024 Earnings Call
Positive tone
PRX-115 Phase 1 results in uncontrolled gout
Elfabrio commercialization with Chiesi
PRX-115 Phase 2 planning
Revenue
$17.96M
▲ 73.6% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Protalix BioTherapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone
Elfabrio commercial sales with Chiesi
PRX-115 for uncontrolled gout
Financial results and revenue decline
Revenue
$13.47M
▼ 61.6% YoY Diluted EPS
$-0.03
▼ 114.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-10
Protalix BioTherapeutics, Inc. Q1 FY2024 Earnings Call
Positive tone
PRX-115 Phase I gout program
Elfabrio commercial launch and Chiesi partnership
Japan BLA for Fabry
Revenue
$3.75M
▼ 60.9% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Protalix BioTherapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
Elfabrio Commercial Launch and Approvals
Revenue Growth and Financial Performance
Chiesi Partnership and Pediatric/Japanese Expansion
Revenue
$10.49M*
▲ 21.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Protalix BioTherapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$10.35M
▼ 27.1% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Protalix BioTherapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$35.08M
▲ 300.7% YoY Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Protalix BioTherapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$9.59M
▼ 40.4% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Protalix BioTherapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$8.62M*
▲ 0.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Protalix BioTherapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$14.18M
▲ 17.7% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Protalix BioTherapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$8.75M
▲ 36.2% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Protalix BioTherapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$16.09M
▲ 42.1% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Protalix BioTherapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$8.55M*
▼ 56.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Protalix BioTherapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$12.05M
▲ 11.7% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Protalix BioTherapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$6.43M
▼ 41.4% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Protalix BioTherapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$11.32M
▼ 47.7% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-16
Protalix BioTherapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$19.50M*
▲ 9.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Protalix BioTherapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$10.79M
▼ 24.3% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Protalix BioTherapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$10.97M
▼ 10.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-06-01
Protalix BioTherapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$21.65M
▲ 107.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Protalix BioTherapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$17.76M*
▼ 34.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1006281
CUSIP
74365A309
13F (30d)
98 filings
96 filers
Visit website
Investor relations